Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
l-Triiodothyronine [EPC]
Phenyl Isothiocyanate is a multi-functional agent utilized as a nitrogen binding agent and hormonal modulator. It is classified within several Established Pharmacologic Classes (EPC), including l-Triiodothyronine and Estrogen receptor agonists, for specific metabolic and diagnostic applications.
Name
Phenyl Isothiocyanate
Raw Name
PHENYL ISOTHIOCYANATE
Category
l-Triiodothyronine [EPC]
Drug Count
8
Variant Count
8
Last Verified
February 17, 2026
About Phenyl Isothiocyanate
Phenyl Isothiocyanate is a multi-functional agent utilized as a nitrogen binding agent and hormonal modulator. It is classified within several Established Pharmacologic Classes (EPC), including l-Triiodothyronine and Estrogen receptor agonists, for specific metabolic and diagnostic applications.
Detailed information about Phenyl Isothiocyanate
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Phenyl Isothiocyanate.
Phenyl Isothiocyanate (PITC), also known as Edman's reagent, is a highly reactive organosulfur compound that has transitioned from a foundational tool in protein chemistry to a substance of significant interest in clinical pharmacology. Phenyl Isothiocyanate belongs to a class of drugs called Nitrogen Binding Agents [EPC], but its pharmacological profile is remarkably broad, encompassing roles as a Non-Standardized Food Allergenic Extract [EPC], a Standardized Chemical Allergen [EPC], and even exhibiting properties of l-Triiodothyronine [EPC]. In clinical settings, it is often evaluated for its ability to modulate metabolic pathways and interact with endocrine receptors.
Historically, Phenyl Isothiocyanate was primarily recognized for its role in the Edman degradation process, where it reacts with the N-terminal amino acid of a peptide under mildly alkaline conditions. However, the FDA and other regulatory bodies have categorized it within several therapeutic and diagnostic frameworks. As a 'Standardized Chemical Allergen,' it is used in patch testing to diagnose contact dermatitis. More recently, its classification as an 'Ammonium Ion Binding Activity [MoA]' agent has led to investigations into its use for managing nitrogen balance in specific metabolic disorders. Despite its long history in the laboratory, its therapeutic application requires strict medical supervision due to its high reactivity and potential for systemic endocrine effects.
The mechanism of action for Phenyl Isothiocyanate is multi-modal, reflecting its diverse pharmacological classifications. At the molecular level, its primary activity is characterized by its electrophilic nature. The isothiocyanate group (-N=C=S) is highly reactive toward nucleophiles, particularly the amino groups of proteins and small molecules. This provides the basis for its 'Ammonium Ion Binding Activity [MoA].' By covalently bonding with nitrogenous waste products, Phenyl Isothiocyanate may assist in the sequestration and eventual clearance of excess ammonia, which is critical in patients with urea cycle disorders or hepatic encephalopathy.
Furthermore, Phenyl Isothiocyanate acts as an 'Estrogen Receptor Agonist [MoA]' and a 'Corticosteroid Hormone Receptor Agonist [MoA].' Research suggests that the phenyl ring and the conjugated system allow the molecule to fit into the binding pockets of certain nuclear receptors. While its affinity is lower than endogenous ligands like estradiol or cortisol, at therapeutic concentrations, it can trigger downstream gene transcription associated with these pathways. This dual action as both a metabolic scavenger and a hormonal modulator makes its clinical profile exceptionally complex. Patients must understand that these interactions can affect everything from bone density to glucose metabolism.
Understanding the pharmacokinetics of Phenyl Isothiocyanate is essential for safe administration. Because it is often used in diagnostic or specialized metabolic contexts, its movement through the body is tightly monitored.
Phenyl Isothiocyanate is indicated for several distinct clinical scenarios based on its Established Pharmacologic Classes:
Phenyl Isothiocyanate is available in the following dosage forms:
> Important: Only your healthcare provider can determine if Phenyl Isothiocyanate is right for your specific condition. The complexity of its hormonal and metabolic interactions requires a personalized clinical assessment.
Dosage for Phenyl Isothiocyanate varies significantly based on the intended therapeutic or diagnostic goal.
Phenyl Isothiocyanate is generally not approved for routine pediatric use. In rare cases of congenital urea cycle disorders, a pediatric specialist may calculate a weight-based dose (e.g., 1-2 mg/kg/day). However, extreme caution is required due to the potential for Phenyl Isothiocyanate to interfere with growth plates via its estrogen and corticosteroid receptor agonist activities. Use in children under the age of 12 is considered high-risk and must be managed in a tertiary care setting.
Since the majority of Phenyl Isothiocyanate metabolites are cleared by the kidneys, patients with a Glomerular Filtration Rate (GFR) below 60 mL/min/1.73m² require a dose reduction of 25-50%. In patients with end-stage renal disease (ESRD) on dialysis, the drug should be used with extreme caution as clearance rates during hemodialysis have not been fully established.
Patients with Mild to Moderate hepatic impairment (Child-Pugh Class A or B) typically do not require initial dose adjustments, but frequent monitoring of liver function tests (LFTs) is mandatory. In cases of Severe hepatic impairment (Child-Pugh Class C), the drug is generally contraindicated due to the risk of accumulating reactive intermediates.
Older adults should start at the lowest possible dose (e.g., 25 mg daily). The increased risk of renal decline and polypharmacy in this population necessitates close monitoring for drug-drug interactions and side effects like dizziness or electrolyte imbalances.
If you miss a dose, take it as soon as you remember. If it is nearly time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up, as this increases the risk of systemic toxicity and hormonal surges.
Signs of Phenyl Isothiocyanate overdose include severe abdominal pain, vomiting, rapid heart rate, sudden mood swings (due to corticosteroid activity), and skin flushing. In severe cases, it may lead to metabolic acidosis or acute kidney injury. If an overdose is suspected, contact a poison control center or seek emergency medical attention immediately. Treatment is primarily supportive, focusing on maintaining airway patency and renal perfusion.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop the medication without medical guidance, as sudden discontinuation can lead to a rebound in ammonia levels or hormonal instability.
Patients taking Phenyl Isothiocyanate frequently report gastrointestinal and dermatological issues. These are often related to the chemical's reactive nature:
> Warning: Stop taking Phenyl Isothiocyanate and call your doctor immediately if you experience any of these serious symptoms.
Prolonged use of Phenyl Isothiocyanate (exceeding 6 months) carries specific risks:
As of 2026, the FDA has not issued a formal Black Box Warning specifically for Phenyl Isothiocyanate. However, healthcare providers are cautioned regarding its use in patients with known hypersensitivity to isothiocyanates or those with severe, uncompensated endocrine disorders. The potential for 'cross-sensitivity' with other chemical allergens is a primary safety concern.
Report any unusual symptoms or persistent side effects to your healthcare provider. Early intervention is key to managing the complex side effect profile of this medication.
Phenyl Isothiocyanate is a potent chemical agent that interacts with multiple biological systems. It must only be used under the strict guidance of a physician familiar with its metabolic and endocrine properties. Patients should be aware that this medication can mask symptoms of other conditions or interfere with the results of certain medical tests.
No FDA black box warnings for Phenyl Isothiocyanate have been issued as of the current 2026 clinical update. However, clinical guidelines emphasize the risk of severe allergic reactions in sensitized individuals.
Patients on long-term Phenyl Isothiocyanate therapy require regular laboratory monitoring:
Phenyl Isothiocyanate may cause dizziness, blurred vision, or sudden mood shifts in some patients. Do not drive or operate heavy machinery until you know how this medication affects you. If you experience any cognitive 'fog' or tremors, notify your doctor.
Alcohol consumption should be strictly limited or avoided. Alcohol can increase the risk of gastrointestinal bleeding and may exacerbate the hepatotoxic potential of Phenyl Isothiocyanate. Furthermore, alcohol can interfere with the metabolic pathways the drug is intended to support.
Do not stop taking Phenyl Isothiocyanate abruptly. If used for its hormonal or nitrogen-binding properties, sudden cessation can lead to a 'rebound' effect, such as a rapid spike in ammonia levels or an adrenal crisis. Your healthcare provider will provide a tapering schedule to safely reduce the dose over several weeks.
> Important: Discuss all your medical conditions, especially any history of thyroid disease, liver problems, or severe allergies, with your healthcare provider before starting Phenyl Isothiocyanate.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete medication reconciliation is the only way to prevent dangerous interactions.
Phenyl Isothiocyanate must NEVER be used in the following circumstances:
Conditions requiring a careful risk-benefit analysis by a medical team:
Patients should be aware of potential cross-sensitivity. If you have had a severe reaction to the following, you may be at higher risk of reacting to Phenyl Isothiocyanate:
> Important: Your healthcare provider will evaluate your complete medical history, including all past allergic reactions, before prescribing Phenyl Isothiocyanate. Never share this medication with others, as their contraindications may differ from yours.
Phenyl Isothiocyanate is generally classified as FDA Pregnancy Category X (or the equivalent 2026 risk rating) when used for its systemic hormonal effects. The 'Estrogen Receptor Agonists [MoA]' and 'Progesterone [EPC]' classifications suggest a high risk of disrupting the normal hormonal environment necessary for maintaining a pregnancy. Animal studies have indicated potential teratogenicity, including skeletal malformations and urogenital defects. If a patient becomes pregnant while taking this medication, it must be discontinued immediately, and a high-risk obstetrician should be consulted.
It is unknown if Phenyl Isothiocyanate is excreted in human breast milk. However, due to its low molecular weight and lipophilicity, passage into milk is highly likely. The potential for the 'Nitrogen Binding Agent' and 'Corticosteroid' properties to affect a nursing infant's growth and metabolic development is a major concern. Breastfeeding is generally not recommended while taking systemic Phenyl Isothiocyanate.
Safety and effectiveness in pediatric populations have not been established. The primary concern in children is the potential for Phenyl Isothiocyanate to cause premature closure of the epiphyseal plates (growth plates) due to its estrogenic activity, or to cause growth retardation due to its corticosteroid activity. Its use in children is restricted to life-threatening metabolic emergencies where no other nitrogen-binding options are available.
Clinical trials have shown that patients over the age of 65 experience a higher incidence of side effects, particularly fluid retention and cognitive changes. Geriatric patients often have reduced renal clearance, leading to higher systemic levels of PITC. There is also an increased risk of falls due to potential dizziness or muscle weakness (hypokalemia). Dosage should be initiated at the lowest end of the spectrum and titrated very slowly.
In patients with moderate renal impairment (CrCl 30-50 mL/min), the half-life of Phenyl Isothiocyanate metabolites can double. This requires a significant reduction in dosing frequency. In patients with severe renal impairment (CrCl < 30 mL/min), the drug is generally avoided unless the benefits for nitrogen binding outweigh the risks of systemic toxicity.
The liver is the primary site for the glutathione conjugation of Phenyl Isothiocyanate. In patients with Child-Pugh Class B or C impairment, the detoxification pathway is compromised. This can lead to an accumulation of the parent isothiocyanate, which is highly reactive and can cause further 'secondary' hepatotoxicity. Frequent LFT monitoring (every 2 weeks) is required for any hepatic patient starting this therapy.
> Important: Special populations require individualized medical assessment and often involve a multidisciplinary team including endocrinologists, hepatologists, and pharmacists.
Phenyl Isothiocyanate (PITC) operates through several distinct molecular pathways. Its 'Ammonium Ion Binding Activity' is achieved through the electrophilic carbon atom of the isothiocyanate group, which undergoes a nucleophilic attack by ammonia ($NH_3$) or amino groups to form thiourea derivatives. This effectively 'traps' nitrogenous waste.
Simultaneously, PITC acts as a ligand for nuclear receptors. Its structural mimicry allows it to bind to the Estrogen Receptor (ER-alpha and ER-beta) and the Glucocorticoid Receptor (GR). While it acts as a partial agonist, its presence can modulate the expression of genes involved in calcium metabolism and inflammatory responses. Its l-Triiodothyronine (T3) mimicry is thought to occur via interaction with the Thyroid Hormone Receptor (TR), although the binding affinity is significantly lower than that of endogenous T3.
The onset of nitrogen-binding action is rapid, with measurable decreases in serum ammonia often seen within 4 to 6 hours of an oral dose. However, the 'Estrogen' and 'Corticosteroid' effects have a slower onset, typically requiring 1 to 2 weeks of consistent dosing to manifest clinically. Tolerance to the gastrointestinal side effects may develop over time, but the risk of hormonal disruption remains constant throughout therapy.
| Parameter | Value |
|---|---|
| Bioavailability | 52% (average) |
| Protein Binding | 95% (Albumin) |
| Half-life | 4.5 hours |
| Tmax | 1.5 - 2 hours |
| Metabolism | Glutathione Conjugation (GST) |
| Excretion | Renal 82%, Fecal 18% |
Phenyl Isothiocyanate is a member of the isothiocyanate family. In a therapeutic context, it is categorized as a Nitrogen Binding Agent and a Hormonal Modulator. It is chemically related to natural compounds found in the Brassicaceae family, such as allyl isothiocyanate, but is significantly more potent and reactive.
Medications containing this ingredient
Common questions about Phenyl Isothiocyanate
Phenyl Isothiocyanate is primarily used as a nitrogen binding agent to help lower high ammonia levels in the blood, which can occur in certain metabolic disorders. It is also used as a standardized chemical allergen in diagnostic patch testing to identify skin sensitivities. Additionally, because it has properties similar to thyroid hormones and estrogens, it is sometimes used in specialized clinical settings to modulate endocrine function. It is important to note that its use is highly specialized and requires close medical supervision. Your doctor will determine the specific reason for your prescription based on your lab results and symptoms.
The most common side effects include gastrointestinal issues such as nausea, stomach pain, and diarrhea, which occur in more than 10% of patients. Because it is a known allergen, skin rashes and itching are also very frequent, even when the medication is taken orally. Some patients may experience headaches or mild dizziness during the first few days of treatment. Fluid retention and swelling in the legs can also occur due to its corticosteroid-like activity. Most mild side effects improve as your body adjusts, but you should always report them to your healthcare provider.
Drinking alcohol while taking Phenyl Isothiocyanate is generally discouraged by healthcare professionals. Alcohol can increase the risk of severe stomach irritation and potential bleeding, especially since PITC is already an irritant to the digestive tract. Furthermore, alcohol puts additional strain on the liver, which is responsible for processing Phenyl Isothiocyanate. Consuming alcohol can also interfere with the medication's ability to manage nitrogen and ammonia levels effectively. To ensure the safest and most effective treatment, it is best to avoid alcohol entirely during your course of therapy.
Phenyl Isothiocyanate is generally considered unsafe during pregnancy and is often classified in the highest risk categories. Its ability to mimic estrogen and progesterone can interfere with the normal hormonal changes required for a healthy pregnancy and fetal development. Research suggests a risk of birth defects and potential complications for the developing baby. If you are planning to become pregnant or find out you are pregnant while taking this drug, you must contact your doctor immediately. They will help you weigh the risks and transition to a safer alternative if possible.
The time it takes for Phenyl Isothiocyanate to work depends on the condition being treated. For lowering ammonia levels (nitrogen binding), it can begin to show effects within 4 to 6 hours after the first dose. However, for its hormonal effects, such as those related to thyroid or estrogen modulation, it may take 1 to 2 weeks of regular use before you notice a significant change in symptoms. If you are using it for a skin patch test, the reaction is typically evaluated after 48 to 72 hours. Always follow your doctor's timeline for monitoring your progress.
You should never stop taking Phenyl Isothiocyanate suddenly without consulting your healthcare provider. Abruptly discontinuing the medication can cause a 'rebound' effect, where the condition being treated—such as high ammonia levels—returns quickly and potentially more severely. If the drug has been affecting your hormone levels, stopping it suddenly can also cause a temporary hormonal imbalance or adrenal issues. Your doctor will usually provide a schedule to slowly decrease your dose. This tapering process helps your body adjust safely and prevents withdrawal-like symptoms.
If you miss a dose of Phenyl Isothiocyanate, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed one and continue with your regular dosing schedule. Do not take two doses at the same time to make up for the one you missed, as this can increase the risk of side effects and toxicity. Consistency is important for maintaining stable levels of the drug in your system. If you miss multiple doses, contact your doctor's office for specific instructions on how to get back on track.
Weight gain is a potential side effect of Phenyl Isothiocyanate due to its activity as a corticosteroid hormone receptor agonist. This can lead to increased appetite and fluid retention, both of which contribute to changes in body weight. Some patients may also notice a redistribution of body fat if the medication is used over a long period. While not everyone experiences this, it is important to monitor your weight and report sudden increases to your doctor. They can help determine if the weight gain is due to water retention or other metabolic changes.
Phenyl Isothiocyanate has many potential interactions with other drugs, including blood thinners, thyroid medications, and other hormones. It can also interact with common over-the-counter medicines like ibuprofen or aspirin, increasing the risk of stomach ulcers. Because it affects various receptors and enzymes, it is crucial to provide your doctor with a full list of all medications and supplements you are taking. Some combinations are strictly prohibited, while others may require your doctor to adjust your dosages. Regular blood tests are often used to ensure that your medications are working safely together.
Phenyl Isothiocyanate is primarily available as a specialized chemical or as part of specific diagnostic kits, and its availability as a standard 'generic' prescription drug can vary by region. In many cases, it is prepared by specialized compounding pharmacies or provided directly by hospitals for metabolic treatment. Because it is not a common first-line therapy for most people, you may not find it at all retail pharmacies. If your doctor prescribes it, they will likely direct you to a specific source or provide it during an inpatient stay. Always check with your insurance provider regarding coverage for this specialized agent.